Regnstrom J - Search Results

1

Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency.

Elsäßer A, Regnstrom J, Vetter T, Koenig F, Hemmings RJ, Greco M, Papaluca-Amati M, Posch M. Elsäßer A, et al. Among authors: regnstrom j. Trials. 2014 Oct 2;15:383. doi: 10.1186/1745-6215-15-383. Trials. 2014. PMID: 25278265 Free PMC article. Review.

2

Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.

Regnstrom J, Koenig F, Aronsson B, Reimer T, Svendsen K, Tsigkos S, Flamion B, Eichler HG, Vamvakas S. Regnstrom J, et al. Eur J Clin Pharmacol. 2010 Jan;66(1):39-48. doi: 10.1007/s00228-009-0756-y. Epub 2009 Nov 20. Eur J Clin Pharmacol. 2010. PMID: 19936724

3

Regulatory watch: Impact of scientific advice from the European Medicines Agency.

Hofer MP, Jakobsson C, Zafiropoulos N, Vamvakas S, Vetter T, Regnstrom J, Hemmings RJ. Hofer MP, et al. Among authors: regnstrom j. Nat Rev Drug Discov. 2015 May;14(5):302-3. doi: 10.1038/nrd4621. Epub 2015 Apr 17. Nat Rev Drug Discov. 2015. PMID: 25881970 No abstract available.

4

Marketing authorisation of orphan medicines in Europe from 2000 to 2013.

Hofer MP, Hedman H, Mavris M, Koenig F, Vetter T, Posch M, Vamvakas S, Regnstrom J, Aarum S. Hofer MP, et al. Among authors: regnstrom j. Drug Discov Today. 2018 Feb;23(2):424-433. doi: 10.1016/j.drudis.2017.10.012. Epub 2017 Oct 23. Drug Discov Today. 2018. PMID: 29074441 Free article. Review.

5

Patient-reported, observer-reported and performance outcomes in qualification procedures at the European Medicines Agency 2013-2018.

Silva M, Moseley J, Vetter T, Regnstrom J, Tome M, Aarum S, Cerreta F, Schabel E, Vamvakas S. Silva M, et al. Among authors: regnstrom j. Br J Clin Pharmacol. 2024 Jan;90(1):299-312. doi: 10.1111/bcp.15907. Epub 2023 Oct 3. Br J Clin Pharmacol. 2024. PMID: 37697483

6

Autoantibodies against modified low-density lipoproteins in coronary artery disease.

Tornvall P, Waeg G, Nilsson J, Hamsten A, Regnström J. Tornvall P, et al. Among authors: regnstrom j. Atherosclerosis. 2003 Apr;167(2):347-53. doi: 10.1016/s0021-9150(03)00021-2. Atherosclerosis. 2003. PMID: 12818418

7

In vitro and in vivo lipolysis of plasma triglycerides increases the resistance to oxidative modification of low-density lipoproteins.

Skoglund-Andersson C, Karpe F, Hellénius ML, Regnström J, Hamsten A, Tornvall P. Skoglund-Andersson C, et al. Among authors: regnstrom j. Eur J Clin Invest. 2003 Jan;33(1):51-7. doi: 10.1046/j.1365-2362.2003.01084.x. Eur J Clin Invest. 2003. PMID: 12492452

8

Phosphatase activity in the arterial wall after balloon injury: effect of somatostatin analog octreotide.

Yamashita M, Dimayuga P, Kaul S, Shah PK, Regnstrom J, Nilsson J, Cercek B. Yamashita M, et al. Among authors: regnstrom j. Lab Invest. 1999 Aug;79(8):935-44. Lab Invest. 1999. PMID: 10462031

9

Serum urate determines antioxidant capacity in middle-aged men - a controlled, randomized diet and exercise intervention study.

Rosell M, Regnström J, Kallner A, Hellénius ML. Rosell M, et al. Among authors: regnstrom j. J Intern Med. 1999 Aug;246(2):219-26. doi: 10.1046/j.1365-2796.1999.00522.x. J Intern Med. 1999. PMID: 10447791 Free article. Clinical Trial.

10

[Lipodystrophy--an adverse effect of protease inhibitors used against HIV infection? Concern about negative delayed effects of this break-through].

Morfeldt L, Jonsson B, Regnström J. Morfeldt L, et al. Among authors: regnstrom j. Lakartidningen. 1998 Oct 14;95(42):4616-7. Lakartidningen. 1998. PMID: 9814016 Review. Swedish. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters